Home › Highland Therapeutics Announces Initiation Of Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
 

Keywords :   


Highland Therapeutics Announces Initiation Of Pivotal Trial Of HLD-200 In Pediatric ADHD Patients

2015-08-05 07:56:18| drugdiscoveryonline Home Page

Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, recently announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has initiated enrolment in a pivotal study to assess the safety and efficacy of HLD-200 – a next-generation formulation of methylphenidate – in children with Attention-Deficit/Hyperactivity Disorder (“ADHD”)

Tags: trial patients adhd announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Strategies to minimize fallback pigs in the nursery
21.09This Week in Agribusiness, Sept. 21, 2024
21.09This Week in Agribusiness, Sept. 21, 2024
21.09RABapp provides rapid response insight in animal health emergencies
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
21.09Weekly Recap: PPG, Axalta, AkzoNobel Top This Weeks Stories
21.09Atlantic Tropical Weather Outlook
More »